Pipeline Innovation : The GLP-1-based therapies will change the treatment of obesity and its comorbidities, including steatotic liver disease, in the future [80] [81], with increasingly sophisticated agents showing even greater efficacy potential
However, like other drugs in its class, tirzepatide shares a similar safety profile, with specific side effects that patients should be aware of
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 60 (Supplement 2), S129-S134
This is not a bariatric multivitamin and does not meet ASMBS guidelines, but it can be used pre-operatively during the liver reduction diet to support nutritional status before surgery
Research on the risk of acute pancreatitis in people taking GLP-1 receptor agonists like semaglutide has shown mixed results
MyObesityTeam is the social network for people with obesity and their loved ones